Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN PRB versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN PRB versus PROBAMPACIN.
POLYCILLIN-PRB vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic